Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 5386 to 5400 of 7684 results

  1. What are the clinical and cost effectiveness, and the safety, of specific antifungal treatments for treating suspected or confirmed COVID-19-associated pulmonary aspergillosis (CAPA), and the optimal treatment duration? When should treatment be started, stopped or modified?

    Recommendation ID NG191/14 Question What are the clinical and cost effectiveness, and the safety, of specific antifungal treatments for

  2. Components of a mental capacity assessment:- What are the components of an effective assessment of mental capacity to make a decision (for example checklists, memory aids or standardised documentation)?

    Recommendation ID NG108/5 Question Components of a mental capacity assessment:- What are the components of an effective assessment of mental

  3. Antibiotics for suspected early-onset infection: What are the core exposures and outcomes that should be used to evaluate clinical effectiveness of antibiotics to prevent or treat early- onset neonatal infection?

    Recommendation ID NG195/14 Question Antibiotics for suspected early-onset infection: What are the core exposures and outcomes that should

  4. Membrane sweeping: What are the effectiveness and acceptability of, and maternal satisfaction with, the following: - multiple versus once-only membrane sweeping, at varying gestational ages, depending on parity - membrane sweeping versus cervical massage?

    Recommendation ID NG207/05 Question Membrane sweeping: What are the effectiveness and acceptability of, and maternal satisfaction with

  5. Information valued by young women with pelvic floor dysfunction: What are the experiences and information needs of young women (between 12 and 17 years) with pelvic floor dysfunction?

    Recommendation ID NG210/17 Question Information valued by young women with pelvic floor dysfunction: What are the experiences and information

  6. Survivorship: What are the experiences of people who are living with, through and beyond a melanoma diagnosis in terms of survivorship and their disease journey?

    Recommendation ID NG14/06 Question Survivorship: What are the experiences of people who are living with, through and beyond a melanoma

  7. People in eligible groups:- What are the important messages and how should they be tailored and delivered to encourage and sustain flu vaccination uptake in eligible groups?

    Recommendation ID NG103/1 Question People in eligible groups:- What are the important messages and how should they be tailored and delivered

  8. Clinical epidemiology of Lyme disease in the UK:- What are the incidence, presenting features, management and outcome of Lyme disease in the UK?

    Recommendation ID NG95/2 Question Clinical epidemiology of Lyme disease in the UK:- What are the incidence, presenting features, management

  9. Neoadjuvant treatment:- What are the indications for postmastectomy radiotherapy after neoadjuvant chemotherapy?

    Recommendation ID NG101/6 Question Neoadjuvant treatment:- What are the indications for postmastectomy radiotherapy after neoadjuvant chemotherapy

  10. Indicator conditions:- What is the UK prevalence of HIV in various indicator conditions, and how effective are interventions using indicator condition-targeted testing compared with other testing strategies?

    Recommendation ID NG60/4 Question Indicator conditions:- What is the UK prevalence of HIV in various indicator conditions, and how effective

  11. Frequency and duration of endoscopic surveillance: What is the usefulness of clinical and molecular biomarkers to inform the optimal frequency and duration of endoscopic surveillance for adults with Barrett's oesophagus?

    Recommendation ID NG231/02 Question Frequency and duration of endoscopic surveillance: What is the usefulness of clinical and molecular

  12. Risk stratification tool to estimate risk of recurrence: What is the utility of a risk stratification tool to estimate the risk of subsequent aneurysmal subarachnoid haemorrhage?

    Recommendation ID NG228/05 Question Risk stratification tool to estimate risk of recurrence: What is the utility of a risk stratification